Clinical trial
Stem Cell Transplantation for Hematological Malignancies
NCT00176839 · Masonic Cancer Center, University of Minnesota, Other · Terminated
Key facts
| NCT number | NCT00176839 |
|---|---|
| Title | Stem Cell Transplantation for Hematological Malignancies |
| Official title | Busulfan, Cyclophosphamide, and Melphalan Followed by Allogeneic Hematopoietic Cell Transplantation in Patients With Hematological Malignancies |
| Lead sponsor | Masonic Cancer Center, University of Minnesota, Other |
| Status | Terminated |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia, Lymphocytic, Acute, AML, MDS |
| Intervention type | Drug, Procedure |
| Interventions | Stem Cell Transplant, Busulfan, Cyclophosphamide, Melphalan, G-CSF, ATG |
| Enrollment | 11 |
| Start date | Jun 7, 2000 |
| Primary completion | Feb 1, 2012 |
| Completion | Feb 1, 2012 |
| First posted | Sep 15, 2005 |
| Last update posted | Dec 5, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: